Furthermore, extensive research has been conducted on the in vivo role of CPU in (the acute phase of) thromboembolic disease, as well as on the hypothesis that high proCPU levels or specific CPB2 gene variants may cause a thrombotic predisposition. This evidence concerns the gene CPB2 and Thromboembolism.